Page 1

Natera Reports Second Quarter 2021 Financial Results Exhibit 99.1 AUSTIN , Texas , August 5 , 2021 / PRNewswire / - Natera , Inc. ( NASDAQ : NTRA ) , a pioneer and global leader in cell - free DNA testing , today reported financial results for the second quarter ended June 30 , 2021 and provided an update on recent business progress and financial outlook . Recent Accomplishments & Highlights • • • Generated total revenues of $ 142.0 million in the second quarter of 2021 compared to $ 86.5 million in the second quarter of 2020 , an increase of 64.2 % . Product revenues grew 70.7 % over the same period . Processed approximately 375,700 tests in the second quarter of 2021 , compared to approximately 234,100 tests processed in the second quarter of 2020 , an increase of 60.5 % . Increased 2021 revenue guidance from $ 550-575 million to $ 600-620 million , the second revenue guidance increase in 2021 . Publication of a new study in Nature , validating the ability of its personalized and tumor - informed circulating tumor DNA ( ctDNA ) assay , SignateraⓇ , to predict outcomes with immunotherapy in a randomized clinical trial . Announced a new publication in JCO Precision Oncology showing 96 % overall survival from a single time point among metastatic colorectal cancer patients who test MRD - negative with Signatera after surgery . Awarded Advanced Diagnostic Laboratory Test ( ADLT ) status for its Signatera MRD test from Centers for Medicare & Medicaid Services ( CMS ) . • Launched the Natera / BGI Signatera Assay , now available to biopharmaceutical customers and clinicians across China . • Announced the Foundation Medicine introduction of Foundation One®Tracker ctDNA Monitoring Assay for Research Use , in partnership with Natera . Announced a phase III trial with GSK using Signatera to identify early - stage breast cancer patients eligible for investigational treatment with niraparib , GSK's PARP inhibitor . Successfully completed $ 551.2 million , net follow - on equity offering in July 2021 . " The second quarter of 2021 was the fastest year on year growth quarter in our history as a publicly traded company , " said Steve Chapman , Natera's Chief Executive Officer . “ Our volumes continued to accelerate , and we expanded our market opportunity with positive new data in both organ health and oncology . As a result of our Q2 performance and the current momentum in the business , we are increasing our revenue guidance for a second time this year , by roughly $ 50 million . " Second Quarter Ended June 30 , 2021 Financial Results Total revenues were $ 142.0 million in the second quarter of 2021 compared to $ 86.5 million for the second quarter of 2020 , an increase of 64.2 % . The product revenues were $ 137.2 million in the second quarter of 2021 compared to $ 80.4 million in the second quarter of 2020 , an increase of 70.7 % . The increase in product revenues was driven by an increase in test volumes compared to the second quarter of 2020. Natera processed approximately 375,700 tests in the second quarter of 2021 , including approximately 361,500 tests accessioned in its laboratory , compared to approximately 234,100 tests processed , including approximately 221,600 tests accessioned in its laboratory , in the second quarter of 2020 .